ArticleVirus evolution2022
Evolutionary analyses of emerging GII.2[P16] and GII.4 Sydney [P16] noroviruses.
Article in Virus evolution, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 27 citations in OpenAlex.
- Human norovirus GII genotypic diversity in Gwangju, South Korea, based on ORF1-ORF2 junction (RdRp-VP1) analysis from 2020 to 2024.Scientific reports · 2026Article
- The increased detection of recombinant norovirus GII.4 Sydney_2012[P16] strains in hospitalized pediatric patients with gastroenteritis in Shanghai, China.BMC infectious diseases · 2026Article
- Superior RdRp Function Drives the Dominance of Prevalent GI.3 Norovirus Lineages.Microorganisms · 2025Article
- Increased GII.3[P12] norovirus outbreaks and viral whole genome analysis in Beijing, China during 2021 and 2023.Gut pathogens · 2025Article
- Epidemiology and genetic diversity of norovirus GII genogroups among pediatric patients in Beijing, China, during 2023-2024.Virology journal · 2025Article
- Molecular Epidemiology of Norovirus Outbreaks in Childcare Centers and Schools in South Korea in 2023.Journal of microbiology and biotechnology · 2025Article
- Article
- Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.Journal of virology · 2025Article
- Eight Years of Norovirus Surveillance in Urban Wastewater: Insights from Next-Generation.Viruses · 2025Article
- Genetic diversity of norovirus in Shenzhen Based on continuous surveillance from 2016 to 2022.Frontiers in cellular and infection microbiology · 2025Article
- A dual typing system establishment and global diversity analysis for sapoviruses.BMC genomics · 2024Article
- Human norovirus disturbs intestinal motility and transit time through its capsid proteins.PLoS pathogens · 2024Article
- In Vitro Culture of Human Norovirus in the Last 20 Years.Biomedicines · 2024Review
- CONFORMATIONAL FLEXIBILITY IS A CRITICAL FACTOR IN DESIGNING BROAD-SPECTRUM HUMAN NOROVIRUS PROTEASE INHIBITORS.bioRxiv : the preprint server for biology · 2024Article
- Biological and immunological characterization of major capsid protein VP1 from distinct GII.2 norovirus clusters.Scientific reports · 2024Article
- Review
- Epidemiological Features of Human Norovirus Genotypes before and after COVID-19 Countermeasures in Osaka, Japan.Viruses · 2024Article
- Editorial: The One Health approach in the context of public health.Frontiers in public health · 2024Article
- Molecular Epidemiology of Human Norovirus Variants from Outbreaks in Zhejiang Province, China, during 2021.Advances in virology · 2024Article
- Predominance of Recombinant Norovirus Strains in Greece, 2016-2018.Microorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GII.2[P16] and GII.4 Sydney [P16] are currently the two predominant norovirus genotypes. This study sought to clarify their evolutionary patterns by analyzing the major capsid VP1 and RNA-dependent RNA polymerase (RdRp) genes. Sequence diversities were analyzed at both nucleotide and amino acid levels. Selective pressures were evaluated with the Hyphy package in different models. Phylogenetic trees were constructed by the maximum likelihood method from full VP1 sequences, and evolutionary rates were estimated by the Bayesian Markov Chain Monte Carlo approach. The results showed that (1) several groups of tightly linked mutations between the RdRp and VP1 genes were detected in the GII.2[P16] and GII.4[P16] noroviruses, and most of these mutations were synonymous, which may lead to a better viral fitness to the host; (2) although the pattern of having new GII.4 variants every 2-4 years has been broken, both the pre- and the post-2015 Sydney VP1 had comparable evolutionary rates to previously epidemic GII.4 variants, and half of the major antigenic sites on GII.4 Sydney had residue substitutions and several caused obvious changes in the carbohydrate-binding surface that may potentially alter the property of the virus; and (3) GII.4 Sydney variants during 2018-21 showed geographical specificity in East Asia, South Asia, and North America; the antigenic sites of GII.2 are strictly conserved, but the GII.2 VP1 chronologically evolved into nine different sublineages over time, with sublineage IX being the most prevalent one since 2018. This study suggested that both VP1 and RdRp of the GII.2[P16] and GII.4 Sydney [P16] noroviruses exhibited different evolutionary directions. GII.4[P16] is likely to generate potential novel epidemic variants by accumulating mutations in the P2 domain, similar to previously epidemic GII.4 variants, while GII.2[P16] has conserved predicted antigenicity and may evolve by changing the properties of nonstructural proteins, such as polymerase replicational fidelity and efficiency. This study expands the understanding of the evolutionary dynamics of GII.2[P16] and GII.4[P16] noroviruses and may predict the emergence of new variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.